Effects of Six-Month Tualang Honey Supplementation on Physiological and Biochemical Profiles in Asymptomatic, Treatment-naïve HIV-infected Patients



  • Suk P. Tang Department of Pharmacology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia
  • Wan N. Wan Yusuf Department of Pharmacology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia
  • Che B. Abd Aziz Department of Physiology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia
  • Mahiran Mustafa Infectious Disease Unit, Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia
  • Maizan Mohamed Faculty of Veterinary Medicine, Universiti Malaysia Kelantan, Pengkalan Chepa, Kota Bharu, Kelantan, Malaysia


Tualang honey, HIV, Asymptomatic, Safety, Biochemical profile, Physiological profile


HIV-infected patients are at higher risk of developing metabolic abnormalities. Honey was reported to be beneficial in various metabolic diseases, yet its long-term effects in HIV patients remained unclear. This study aims to evaluate the safety of six-month Tualang honey supplementation in asymptomatic, treatment-naïve HIV-infected patients based on basic physiological and biochemical profiles. This is a randomised, controlled, open-labelled study. A total of 95 asymptomatic, treatment-naïve HIV-infected patients with CD4 counts between 250 to 600 cells/mm3 were recruited in this study. Tualang honey supplementation at three different doses (20 g, 40 g and 60 g) were given daily for a total of six-month period. Control group was not supplemented with any honey. Body weight, body mass index (BMI), blood pressure (BP), serum glucose, lipid profiles, renal and liver function tests were measured at baseline, threemonth and six-month follow-up. An increase in the mean total cholesterol (32% from baseline) was observed in control group at six-month follow up. The mean total cholesterol and other measured parameters were relatively maintained in Tualang honey-supplemented groups. A significant increase (p = 0.003) in the blood glucose was observed in group receiving 60 g honey at six-month follow-up but the level was still within normal range. In conclusion, at the doses and duration tested. Tualang honey supplementation is safe to be given and may potentially delay dyslipidaemia progression in treatment-naïve HIV-infected patients. 


World Health Organization. Ten threats to global health in 2019. [Online]. 2020 [cited 2020 Aug 10]. Available from: https://www.who.int/news-room/spotlight/tenthreats-to-global-health-in-2019.

World Health Organization. HIV/AIDS. [Online]. 2020 [cited 2020 Jul 30]. Available from: https://www.who.int/news-room/fact-sheets/detail/hivaids.

Ministry of Health Malaysia. Country progress report on HIV/AIDS 2019 - Malaysia. [Online]. 2019 [cited 2020 Aug 31]. Available from:


Abdulrahman SA, Rampal L, Ibrahim F, Radhakrishnan AP, Kadir Shahar H, Othman N. Mobile phone reminders and peer counseling improve adherence and treatment outcomes of patients on ART in Malaysia: a randomized clinical trial. PLoS One. 2017; 12(5):e0177698.

Willig AL and Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016; 13(5):289- 296.

Brener MI, Post WS, Haberlen SA, Zhang L, Palella FJ Jr, Jacobson LP, Dobs AS, George RT, Witt MD, Budoff M, Kingsley LA, Brown TT. Comparison of insulin resistance to coronary atherosclerosis in human immunodeficiency virus infected and uninfected men (from the multicenter AIDS cohort study). Am J Cardiol. 2016; 117(6):993-1000.

Okeke NL, Davy T, Eron JJ, Napravnik S. Hypertension among HIV-infected patients in clinical care, 1996-2013. Clin Infect Dis. 2016; 63(2):242-248.

Ivanov AV, Valuev-Elliston VT, Ivanova ON,Kochetkov SN, Starodubova ES, Bartosch B, Isaguliants MG. Oxidative stress during HIV infection: mechanisms and consequences. Oxid Med Cell Longev. 2016; 2016:8910396.

Kishore RK, Halim AS, Syazana MSN, Sirajudeen KNS. Tualang honey has higher phenolic content and greater radical scavenging activity compared with other honey sources. Nutr Res. 2011; 31(4):322-325.

Khalil MI, Alam N, Moniruzzaman M, Sulaiman SA, Gan SH. Phenolic acid composition and antioxidant properties of Malaysian honeys. J Food Sci. 2011; 76(6):C921-928.

Zakaria Z, Zainal Abidin ZF, Gan SH, Wan Abdul Hamid WZ, Mohamed M. Effects of honey supplementation on safety profiles among

postmenopausal breast cancer patients. J Taibah Univ Med Sci. 2018; 13(6):535-540.

Ismail SB, Bakar MB, Nik Hussain NH, Norhayati MN, Sulaiman SA, Jaafar H, Draman S, Ramli R, Wan Yusoff WZ. Comparison on the effects and safety of Tualang honey and Tribestan in sperm parameters, erectile function, and hormonal profiles among oligospermic males. Evid Based Complement Alternat Med. 2014; 2014:126138.

Muhamad R, Draman N, Aziz AA, Abdullah S, Jaeb MZM. The effect of Tualang honey on the quality of life of patients with chronic obstructive pulmonary disease: a randomized controlled trial. J Taibah Univ Med Sci. 2017; 13(1):42-50.

Haron, MN, Rahman, WFWA, Sulaiman, SA, Mohamed, M. Tualang honey ameliorates restraint stress-induced impaired pregnancy outcomes in rats. Eur J Integr Med. 2014; 6(6):657-663.

Erejuwa OO, Sulaiman SA, Wahab MS, Sirajudeen KN, Salleh MS, Gurtu S. Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats. Int J Biol Sci. 2011; 7(2):244-252.

Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000; 31(3):803-805.

Grinspoon S and Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36(2):S69-78.

Woods MN, Spiegelman D, Knox TA, Forrester JE, Connors JL, Skinner SC, Silva M, Kim JH, Gorbach SL. Nutrient intake and body weight in a large HIV cohort that includes women and minorities. J Am Diet Assoc. 2002; 102(2):203-211.

Alo C, Ogbonnaya LU, Azuogu BN. Effects of nutrition counseling and monitoring on the weight and hemoglobin of patients receiving antiretroviral therapy in Ebonyi State, Southeast Nigeria. HIV/AIDS - Res. Palliat Care. 2014; 6:91-97.

Martinez SS, Campa A, Bussmann H, Moyo S, Makhema J, Huffman FG, Williams OD, Essex M, Marlink R, Baum MK. Effect of BMI and fat mass on HIV disease progression in HIV-infected, antiretroviral treatment-naïve adults in Botswana. Br J Nutr. 2016; 115(12):2114-2121.

World Health Organization. Nutrient requirements for people living with HIV/AIDS : report of a technical consultation. [Online]. 2003 [cited 2020 Aug 30]. Available from: https://www.who.int/nutrition/publications/Content_nutrient_requirements.pdf.

Kearns A, Gordon J, Burdo TH, Qin X. HIV-1- associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol. 2017; 69(25):3084-3098.

Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV/AIDS Rep. 2016; 13(4):218-225.

Salami AK, Akande AA, Olokoba AB. Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies. West Afr J Med. 2009; 28(1):10-15.

Ab Wahab SZ, Nik Hussain NH, Zakaria R, Abdul Kadir A, Mohamed N, Tohit NM, Norhayati MN, Hassan II. Long-term effects of honey on cardiovascular parameters and anthropometric measurements of postmenopausal women. Complement Ther Med. 2018; 41:154-160.

Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, Boccara F, Capeau J. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019; 18(9):829-840.

Willig AL and Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016; 13(5):289- 296.

Isezuo SA and Makusidi MA. Metabolic dysfunctions in non-antiretroviral treated HIV/AIDS patients. Niger J Clin Pract. 2009; 12(4):375-378.

Yaacob LH, Nik Hussain NH, Abdul Kadir A, Mohd Noor N, Sulaiman SA, Hassan II, Ismail SB, Haron J, Musa KI. Safety of Honey in Postmenopausal Women. Int Med J. 2013; 20(1):25-28.

Bekkaye I, Azzoug S, Dahmoun K, Chentli F. Effects of natural honey intake on glycaemic control and lipid profile in type 2 diabetes. J Nutr Sci & Diet. 2016; 2(1):36-42.

Bahrami M, Ataie-Jafari A, Hosseini S, Foruzanfar MH, Rahmani M, Pajouhi M. Effects of natural honey consumption in diabetic patients: an 8-week randomized clinical trial. Int J Food Sci Nutr. 2009; 60(7):618-626.

Enginyurt O, Cakir L, Karatas A, Cankaya S, Kaya Y, Tugcu H, Iscanli M, Cankaya N, Yarilgac S. The role of pure honey in the treatment of diabetes mellitus. Biomed Res. 2017; 28(7):3305-3312.

Al-Waili NS. Effects of daily consumption of honey solution on hematological indices and blood levels of minerals and enzymes in normal individuals. J Med Food. 2003; 6(2):135-140.

Arcot J and Brand-Miller J. A preliminary assessment of the glycaemic index of honey: a report for the rural industries research and development corporation. Australian Gov Rural Ind Res Dev Corp. 2005; 5(27):1- 28.

Abdulrhman M, El Hefnawy M, Ali R, Abdel Hamid I, Abou El-Goud A, Refai D. Effects of honey, sucrose and glucose on blood glucose and C-peptide in patients with type 1 diabetes mellitus. Compl Ther Clin Pract. 2013; 19(1):15-19.

Robert SD and Ismail AA. Two varieties of honey that are available in Malaysia gave intermediate glycemic index values when tested among healthy individuals. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009; 153(2):145-147.

Wyatt CM, Shi Q, Novak JE, Hoover DR, Szczech L, Mugabo JS, Binagwaho A, Cohen M, Mutimura E, Anastos K. Prevalence of kidney disease in HIVinfected and uninfected Rwandan women. PLoS One 2011; 6(3):e18352.

Crum-Cianflone N, Ganesan A, Teneza-Mora N, Riddle M, Medina S, Barahona I, Brodine S. Prevalence and factors associated with renal dysfunction among HIVinfected patients. AIDS Patient Care STDS. 2010; 24(6):353-360.

Anyabolu EN, Chukwuonye II, Arodiwe E, Ijoma CK, Ulasi I. Prevalence and predictors of chronic kidney disease in newly diagnosed human immunodeficiency virus patients in Owerri, Nigeria. Indian J Nephrol. 2016; 26(1):10-15.

De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, Winston A, Reiss P, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study and the AGEhIV Cohort Study. Patterns of co-occurringcomorbidities in people living with HIV. Open Forum Infect Dis. 2018; 5(11):272.

Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. Subst Abuse Treat Prev Pol. 2019; 14:52.

Pillaye JN, Marakalala MJ, Khumalo N, Spearman W, Ndlovu H. Mechanistic insights into antiretroviral druginduced liver injury. Pharmacol Res Perspect. 2020; 8(4):e00598.

Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis. 2011; 24(1):12-18.

Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017; 31(11):1621-1632.

Zachariah S, Kumar K, Lee SWH, Choon WY, Naeem S, Leong C. Interpretation of laboratory data and general physical examination by pharmacists. Clin Pharm Edu Practice and Res Elsevier; 2019; D:91-108.




How to Cite

Tang, S. P., Yusuf, W. N. W., Aziz, C. B. A., Mustafa, M., & Mohamed, M. (2020). Effects of Six-Month Tualang Honey Supplementation on Physiological and Biochemical Profiles in Asymptomatic, Treatment-naïve HIV-infected Patients: doi.org/10.26538/tjnpr/v4i12.14. Tropical Journal of Natural Product Research (TJNPR), 4(12), 1116–1123. Retrieved from https://www.tjnpr.org/index.php/home/article/view/889